Back to INSMView Full Landscape
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
7 competitors in Hidradenitis Suppurativa
ABBVlutikizumab
Phase 3INCYINCB054707
Phase 2INCYPlacebo
Phase 2ACRSPlacebo oral tablet
Phase 2TXMDATI-450
Phase 2Drug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA11/18/2025
Brinsupri
Brinsupri is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in patients 12 years of age and older with two or more exacerbations in the prior 12 months.
PRIME
View on EMADrug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
